Cargando…

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

The worldwide burden of cancers is increasing at a very high rate, including the aggressive and resistant forms of cancers. Certain levels of breakthrough have been achieved with the conventional treatment methods being used to treat different forms of cancers, but with some limitations. These limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Omole, Richard Kolade, Oluwatola, Oluwaseyi, Akere, Millicent Tambari, Eniafe, Joseph, Agboluaje, Elizabeth Oladoyin, Daramola, Oluwafemi Bamidele, Ayantunji, Yemisi Juliet, Omotade, Temiloluwa Ifeoluwa, Torimiro, Nkem, Ayilara, Modupe Stella, Adeyemi, Oluwole Isaac, Salinsile, Olubusola Sajanat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772532/
https://www.ncbi.nlm.nih.gov/pubmed/36569326
http://dx.doi.org/10.3389/fphar.2022.1082797
_version_ 1784854999180771328
author Omole, Richard Kolade
Oluwatola, Oluwaseyi
Akere, Millicent Tambari
Eniafe, Joseph
Agboluaje, Elizabeth Oladoyin
Daramola, Oluwafemi Bamidele
Ayantunji, Yemisi Juliet
Omotade, Temiloluwa Ifeoluwa
Torimiro, Nkem
Ayilara, Modupe Stella
Adeyemi, Oluwole Isaac
Salinsile, Olubusola Sajanat
author_facet Omole, Richard Kolade
Oluwatola, Oluwaseyi
Akere, Millicent Tambari
Eniafe, Joseph
Agboluaje, Elizabeth Oladoyin
Daramola, Oluwafemi Bamidele
Ayantunji, Yemisi Juliet
Omotade, Temiloluwa Ifeoluwa
Torimiro, Nkem
Ayilara, Modupe Stella
Adeyemi, Oluwole Isaac
Salinsile, Olubusola Sajanat
author_sort Omole, Richard Kolade
collection PubMed
description The worldwide burden of cancers is increasing at a very high rate, including the aggressive and resistant forms of cancers. Certain levels of breakthrough have been achieved with the conventional treatment methods being used to treat different forms of cancers, but with some limitations. These limitations include hazardous side effects, destruction of non-tumor healthy cells that are rapidly dividing and developing, tumor resistance to anti-cancer drugs, damage to tissues and organs, and so on. However, oncolytic viruses have emerged as a worthwhile immunotherapeutic option for the treatment of different types of cancers. In this treatment approach, oncolytic viruses are being modeled to target cancer cells with optimum cytotoxicity and spare normal cells with optimal safety, without the oncolytic viruses themselves being killed by the host immune defense system. Oncolytic viral infection of the cancer cells are also being genetically manipulated (either by removal or addition of certain genes into the oncolytic virus genome) to make the tumor more visible and available for attack by the host immune cells. Hence, different variants of these viruses are being developed to optimize their antitumor effects. In this review, we examined how grave the burden of cancer is on a global level, particularly in sub-Saharan Africa, major conventional therapeutic approaches to the treatment of cancer and their individual drawbacks. We discussed the mechanisms of action employed by these oncolytic viruses and different viruses that have found their relevance in the fight against various forms of cancers. Some pre-clinical and clinical trials that involve oncolytic viruses in cancer management were reported. This review also examined the toxicity and safety concerns surrounding the adoption of oncolytic viro-immunotherapy for the treatment of cancers and the likely future directions for researchers and general audience who wants updated information.
format Online
Article
Text
id pubmed-9772532
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97725322022-12-23 Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy Omole, Richard Kolade Oluwatola, Oluwaseyi Akere, Millicent Tambari Eniafe, Joseph Agboluaje, Elizabeth Oladoyin Daramola, Oluwafemi Bamidele Ayantunji, Yemisi Juliet Omotade, Temiloluwa Ifeoluwa Torimiro, Nkem Ayilara, Modupe Stella Adeyemi, Oluwole Isaac Salinsile, Olubusola Sajanat Front Pharmacol Pharmacology The worldwide burden of cancers is increasing at a very high rate, including the aggressive and resistant forms of cancers. Certain levels of breakthrough have been achieved with the conventional treatment methods being used to treat different forms of cancers, but with some limitations. These limitations include hazardous side effects, destruction of non-tumor healthy cells that are rapidly dividing and developing, tumor resistance to anti-cancer drugs, damage to tissues and organs, and so on. However, oncolytic viruses have emerged as a worthwhile immunotherapeutic option for the treatment of different types of cancers. In this treatment approach, oncolytic viruses are being modeled to target cancer cells with optimum cytotoxicity and spare normal cells with optimal safety, without the oncolytic viruses themselves being killed by the host immune defense system. Oncolytic viral infection of the cancer cells are also being genetically manipulated (either by removal or addition of certain genes into the oncolytic virus genome) to make the tumor more visible and available for attack by the host immune cells. Hence, different variants of these viruses are being developed to optimize their antitumor effects. In this review, we examined how grave the burden of cancer is on a global level, particularly in sub-Saharan Africa, major conventional therapeutic approaches to the treatment of cancer and their individual drawbacks. We discussed the mechanisms of action employed by these oncolytic viruses and different viruses that have found their relevance in the fight against various forms of cancers. Some pre-clinical and clinical trials that involve oncolytic viruses in cancer management were reported. This review also examined the toxicity and safety concerns surrounding the adoption of oncolytic viro-immunotherapy for the treatment of cancers and the likely future directions for researchers and general audience who wants updated information. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9772532/ /pubmed/36569326 http://dx.doi.org/10.3389/fphar.2022.1082797 Text en Copyright © 2022 Omole, Oluwatola, Akere, Eniafe, Agboluaje, Daramola, Ayantunji, Omotade, Torimiro, Ayilara, Adeyemi and Salinsile. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Omole, Richard Kolade
Oluwatola, Oluwaseyi
Akere, Millicent Tambari
Eniafe, Joseph
Agboluaje, Elizabeth Oladoyin
Daramola, Oluwafemi Bamidele
Ayantunji, Yemisi Juliet
Omotade, Temiloluwa Ifeoluwa
Torimiro, Nkem
Ayilara, Modupe Stella
Adeyemi, Oluwole Isaac
Salinsile, Olubusola Sajanat
Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title_full Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title_fullStr Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title_full_unstemmed Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title_short Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
title_sort comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772532/
https://www.ncbi.nlm.nih.gov/pubmed/36569326
http://dx.doi.org/10.3389/fphar.2022.1082797
work_keys_str_mv AT omolerichardkolade comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT oluwatolaoluwaseyi comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT akeremillicenttambari comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT eniafejoseph comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT agboluajeelizabetholadoyin comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT daramolaoluwafemibamidele comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT ayantunjiyemisijuliet comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT omotadetemiloluwaifeoluwa comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT torimironkem comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT ayilaramodupestella comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT adeyemioluwoleisaac comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy
AT salinsileolubusolasajanat comprehensiveassessmentontheapplicationsofoncolyticvirusesforcancerimmunotherapy